128 related articles for article (PubMed ID: 15556058)
1. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.
Lalukota K; Cleland JG; Ingle L; Clark AL; Coletta AP
Eur J Heart Fail; 2004 Dec; 6(7):953-5. PubMed ID: 15556058
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
3. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
[TBL] [Abstract][Full Text] [Related]
4. Contemporary medical management of left ventricular dysfunction and congestive heart failure.
Teo KK; Ignaszewski AP; Gutierrez R; Hill KL; Martin SL; Calhoun HP; Humen DP; Montague TJ
Can J Cardiol; 1992; 8(6):611-9. PubMed ID: 1354569
[TBL] [Abstract][Full Text] [Related]
5. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
[TBL] [Abstract][Full Text] [Related]
6. [Trends in pharmacological treatment of congestive heart failure].
Halawa B
Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Dulin BR; Krum H
Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
[TBL] [Abstract][Full Text] [Related]
8. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
11. [Drug therapy of cardiac insufficiency: status 1995].
Rickenbacher P; Buser P; Osswald S; Pfisterer M
Schweiz Med Wochenschr; 1996 May; 126(21):933-45. PubMed ID: 8693314
[TBL] [Abstract][Full Text] [Related]
12. Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment.
Andersson B; Kjörk E; Brunlöf G
Int J Cardiol; 2005 Oct; 104(3):257-63. PubMed ID: 16186053
[TBL] [Abstract][Full Text] [Related]
13. Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly.
O'Connor CM; Arumugham P
Clin Geriatr Med; 2007 Feb; 23(1):141-53. PubMed ID: 17126759
[TBL] [Abstract][Full Text] [Related]
14. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
[TBL] [Abstract][Full Text] [Related]
15. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
[TBL] [Abstract][Full Text] [Related]
16. Experience with beta blockers in heart failure mortality trials.
Eichhorn EJ
Clin Cardiol; 1999 Oct; 22 Suppl 5():V21-9. PubMed ID: 10526700
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
18. Device based treatment of heart failure.
Patwala AY; Wright DJ
Postgrad Med J; 2005 May; 81(955):286-91. PubMed ID: 15879039
[TBL] [Abstract][Full Text] [Related]
19. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
Bristow MR; Krause-Steinrauf H; Nuzzo R; Liang CS; Lindenfeld J; Lowes BD; Hattler B; Abraham WT; Olson L; Krueger S; Thaneemit-Chen S; Hare JM; Loeb HS; Domanski MJ; Eichhorn EJ; Zelis R; Lavori P
Circulation; 2004 Sep; 110(11):1437-42. PubMed ID: 15337700
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial.
Zampino M; O'Connor CM; Gattis WA; Adams KF; Gheorghiade M
Am Heart J; 2003 Feb; 145(2 Suppl):S62-6. PubMed ID: 12594456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
